#75 - David Light: Zantac recall due to cancer concerns – what you need to know

Oct 14, 2019 Episode Page ↗
Overview

David Light, CEO of Valisure, discusses their discovery of high levels of NDMA, a probable human carcinogen, in Zantac/ranitidine due to the drug's inherent instability. He explains Valisure's unique drug testing model and the FDA's tempered reaction, offering recommendations for consumers.

At a Glance
12 Insights
1h 37m Duration
19 Topics
6 Concepts

Deep Dive Analysis

Introduction to Valisure: An Analytical Pharmacy

Motivation for Valisure: Problems with Generic Drugs

Valisure's Technology and Business Model

The Valsartan Recall: Carcinogens in Blood Pressure Medication

Understanding Solvents and Manufacturing Contaminants

FDA's Oversight Limitations and Self-Reporting Issues

Ranitidine (Zantac): Ubiquitous Drug and Initial Concerns

Valisure's Discovery of High NDMA in Ranitidine

Ranitidine's Inherent Instability and NDMA Formation

NDMA: Mechanism of Carcinogenesis and Animal Models

Epidemiological Challenges and Unanswered Questions

The Stanford Study on Ranitidine and NDMA in Urine

Valisure's Proposed Biological Link for NDMA Formation

FDA's Response to Valisure's Citizen Petition

International Recalls of Ranitidine vs. FDA's Stance

Debate on Testing Methodology: Temperature and NDMA Generation

Valisure's Low-Temperature Testing and Simulated Gastric Fluid Results

Asymmetric Risk of FDA's Inaction on Ranitidine

Proper Disposal of Ranitidine to Prevent Environmental Contamination

Valisure

Valisure is an online pharmacy and analytical laboratory that chemically validates samples from every single batch of every medication before dispensing it to patients. This process screens out problematic batches and provides a certificate of analysis, similar to a nutrition label for food.

GMP (Good Manufacturing Practices)

GMP refers to hundreds of documents and systems that are required by the FDA for any manufacturing process under its purview. It's designed to ensure consistency, proper documentation, and to catch errors or problems, including manufacturing changes, but relies on self-reporting by manufacturers.

Solvent

A solvent is a substance used to dissolve different chemical components during a reaction, analogous to water in cooking. Changes in solvents during drug manufacturing, such as switching from water to oil, can lead to unintended side reactions and the creation of impurities or contaminants.

NDMA (Nitrosodimethylamine)

NDMA is a probable human carcinogen that has been extensively studied since the 1950s and is known to be extremely potent. It causes cancer by sticking to and modifying DNA, and is actively used as a control to induce cancer in rats for research purposes.

Ranitidine Instability

Ranitidine, the active ingredient in Zantac, is an inherently unstable molecule that can degrade and directly form NDMA. This degradation can occur under various conditions, including heat, and even within the human body, leading to significant NDMA exposure.

DDAH1 Enzyme

DDAH1 is an enzyme identified by Valisure through computational modeling as a potential biological mechanism for ranitidine to form NDMA. This enzyme can break off a DMA group from ranitidine, making it easier to form NDMA throughout the body, even outside the stomach.

?
Why is independent chemical testing of medications necessary?

The FDA does not chemically test the vast majority of medications; testing is often done by manufacturers, mostly overseas, and self-reported to the FDA, a system prone to problems and fraud.

?
What was the problem with Valsartan and other ARB medications?

Manufacturing changes, often overseas, led to the creation of impurities, including potent carcinogens like NDMA and DMF, which were found in the drugs for years before detection and recall.

?
What is NDMA and how dangerous is it?

NDMA (nitrosodimethylamine) is a probable human carcinogen that has been heavily studied since the 1950s and is known to damage DNA, causing cancer; it is even used to induce cancer in rats for studies.

?
Why is ranitidine (Zantac) a concern regarding NDMA?

Valisure discovered that ranitidine is an inherently unstable molecule that can degrade and form millions of nanograms of NDMA, a potent carcinogen, even under mild conditions like heat or in the human body.

?
How much NDMA can ranitidine produce in the body?

A 2016 Stanford study found over 40,000 nanograms of NDMA in the urine of subjects after a single Zantac pill, suggesting millions of nanograms were exposed in the body due to NDMA's low renal clearance.

?
Why did the FDA's initial response to ranitidine concerns differ from other countries?

The FDA initially stated they found NDMA at 'low levels' and focused on contamination, while many other countries, realizing the inherent instability of the drug, issued stronger recalls or bans for all ranitidine products.

?
Is Valisure's testing method for ranitidine flawed due to heat generating NDMA?

Valisure acknowledges that heat can generate NDMA from ranitidine, but they also developed a low-temperature testing method that, when used with simulated gastric fluid, still showed hundreds of thousands of nanograms of NDMA formation, validating the drug's instability in body-relevant conditions.

?
What should individuals do if they are currently taking Zantac/ranitidine?

It is recommended to stop taking the drug and consult with a doctor for alternative medications, as there are many equally effective substitutes available.

?
How should ranitidine products be disposed of?

Ranitidine should not be flushed down the toilet or thrown in the trash, as it can degrade into NDMA in wastewater treatment plants and contaminate drinking water; it should be returned to a pharmacy or a medication disposal facility.

1. Immediately Stop Taking Ranitidine

Cease taking ranitidine (Zantac) immediately, regardless of brand or generic, because the drug molecule itself is highly unstable and degrades into NDMA, a potent carcinogen, under various conditions, including those found in the human body.

2. Dispose of Ranitidine Properly

Do not flush ranitidine down the toilet or throw it in the trash, as it can degrade into NDMA in wastewater treatment plants and contaminate drinking water; instead, return it to a pharmacy or designated medication disposal facility.

3. Seek Gastric Acid Alternatives

If taking ranitidine for gastric acid reduction, consult your doctor to switch to an equally efficacious alternative, as many safe and effective options exist without the inherent risk of NDMA formation.

4. Chemically Validate All Medications

Consider using pharmacies that chemically validate every batch of medication they dispense, as the FDA does not perform this testing on most drugs, and self-reporting by overseas manufacturers can lead to quality issues.

5. Scrutinize ARB Blood Pressure Drugs

If taking or prescribing ARB medications (e.g., Valsartan, Losartan), be aware of ongoing recalls due to contamination with potent carcinogens like NDMA and DMF, which vary by manufacturer and batch.

6. Verify Drug Purity By Batch

Recognize that drug quality can vary significantly even from the same manufacturer across different batches; therefore, seek batch-specific chemical validation rather than relying on general manufacturer reputation.

7. Prioritize Trustworthy Information Sources

When consuming information, especially about health, prioritize sources that are not influenced by financial incentives from companies, as this ensures an honest relationship and unbiased advocacy.

8. Understand Asymmetric Health Risk

When making health decisions, particularly regarding medications, evaluate the asymmetry of risk by weighing the potentially infinite downside of inaction against the limited upside of maintaining the status quo, especially when safe alternatives exist.

9. Critically Evaluate FDA Statements

When the FDA makes statements about drug safety, particularly when independent findings suggest otherwise, critically evaluate the underlying data and methodology, as initial assessments may not always capture the full scope of a problem.

10. Question Generic Drug Consistency

Be aware that generic medications can vary significantly (up to 45% in bioequivalence) from brand-name drugs or other generics, which may lead to inconsistent effects or side effects.

11. Recognize Regulatory Oversight Limits

Understand that regulatory bodies like the FDA have limited resources and rely heavily on self-reported data from manufacturers, meaning not all medications are chemically tested by the regulator, which can lead to quality issues.

12. Optimize Health and Longevity

Actively seek and synthesize information to optimize performance, health, and longevity, as this approach can lead to a higher quality and more fulfilling life.

You don't buy food without looking at the nutrition label and seeing what's in it, but where is that for your medications?

David Light

NDMA is literally one of the best studied, most potent carcinogens known to man. It's actually used as a control to induce cancer in rats.

David Light

The ideal level is zero and we were seeing millions.

David Light

This was a problem must be at just a totally different level as in the drug itself is just so incredibly unstable and not just unstable in terms of, okay, maybe you're going to get a less potent pill. It's directly forming NDMA, the extremely potent carcinogen.

David Light

The renal clearance of NDMA, so how much NDMA actually makes it into the urine, is that often 1% or less. And that's because NDMA sticks to DNA and your body is full of DNA and it's reacting all over your body.

David Light

The FDA's statement Friday the 13th, September the 13th, was... that they had found an impurity in DMA at low levels. I think they made some references to barely exceeding those that's in food. Kind of feels like no big deal, but they're still making an alert and wanted everybody to be aware of that.

David Light

Current evidence suggests that NDMA may be present in ranitidine regardless of the manufacturer, which directly underscores what we were finding, that it doesn't matter how it was made or where it was made, just that the drug itself is so incredibly fundamentally unstable that it can directly form NDMA in a whole variety of conditions and should just be taken off the market.

David Light

Heating the sample generates NDMA. I mean, they don't mention us specifically, but they do say third party laboratory, which ironically in the press, I don't think they even bothered talking about that. They just inserted the name Balisher. But I think at the very least nicely underscores that even just some heat, which again is benign for practically all these other molecules is enough to generate NDMA.

David Light

This is a very asymmetric bet that the FDA is making.

Peter Attia

Proper Ranitidine Disposal

David Light
  1. Do not flush ranitidine down the toilet.
  2. Do not throw ranitidine in the trash.
  3. Return ranitidine to a pharmacy or a medication disposal facility for proper disposal as toxic waste.
80%
Percentage of drug products in the United States manufactured overseas Manufactured in either India or China
45%
Allowed variation in bioequivalence between generic drugs From one another
Over twofold
Increased chance of seizure associated with refilling anti-epileptic medication According to a Harvard Medical School study with almost 2000 patients
Roughly 15 million
Annual ranitidine prescriptions filled in the United States In 2016, placing it in the top 50 most prescribed drugs
96 nanograms
FDA's maximum permissible exposure to NDMA Calculated to ensure less than one cancer case in 100,000 over 70 years
Between two and three million nanograms per dose
NDMA detected by Valisure in ranitidine (initial finding) Five orders of magnitude higher than FDA limit
1983
Year ranitidine was approved in the United States Molecule approved in 1981, first concerns raised in 1982
17 years
Years of research on ranitidine's instability and NDMA formation in water supply By Professor Bill Mitch and colleagues
130 degrees Celsius
Temperature of GCMS oven for standard NDMA analysis Part of FDA standard protocol for most drugs
15 minutes
Incubation time in GCMS oven for ranitidine analysis Leading to significant NDMA conversion
Over 40,000 nanograms
NDMA found in urine after a single Zantac pill From a 2016 Stanford University clinical study by Zhang and Mitch
Around 4 million nanograms
Estimated NDMA exposure in the body from a single Zantac pill Based on NDMA's renal clearance often being 1% or less
Up to 300,000 nanograms
NDMA found in simulated gastric fluid using low-temperature testing Valisure's findings, similar to Bill Mitch's 400,000 nanograms
Roughly 30
Number of countries that have recalled or banned ranitidine As of a few weeks after the September 13th FDA announcement